CoChat

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate

Open access
Boubia, Benaïssa, Poupardin, Olivia, Barth, Martine, Binet, Jean, Peralba, Philippe, Mounier, Laurent, Jacquier, Elise, Gauthier, Emilie, Lepais, Valérie, Chatar, Maryline, Ferry, Stéphanie, Thourigny, Anne, Guillier, Fabrice, Llacer, Jonathan, Amaudrut, Jérome, Dodey, Pierre, Lacombe, Olivier, Masson, Philippe, Montalbetti, Christian, Wettstein, Guillaume, Luccarini, Jean-Michel, Legendre, Christiane, Junien, Jean-Louis, Broqua, Pierre · 2018 · Journal of Medicinal Chemistry
Cited by 110

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Here, we describe the identification and synthesis of novel indole sulfonamide derivatives that activate the three peroxisome proliferator activated receptor (PPAR) isoforms. Starting with a PPARα activator, compound 4, identified during a high throughput screening (HTS) of our proprietary screening library, a systematic optimization led to the discovery of lanifibranor (IVA337) 5, a moderately potent and well balanced pan PPAR agonist with an excellent safety profile. In vitro and in vivo, compound 5 demonstrated strong activity in models that are relevant to nonalcoholic steatohepatitis (NASH) pathophysiology suggesting therapeutic potential for NASH patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b01285

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 110

Metadata

Authors
Boubia, B., Poupardin, O., Barth, M., Binet, J., Peralba, P., Mounier, L., Jacquier, E., Gauthier, E., Lepais, V., Chatar, M., Ferry, S., Thourigny, A., Guillier, F., Llacer, J., Amaudrut, J., Dodey, P., Lacombe, O., Masson, P., Montalbetti, C., Wettstein, G., Luccarini, J.-M., Legendre, C., Junien, J.-L., & Broqua, P.
Venue
Journal of Medicinal Chemistry
Published
2018-02-15
Volume
61
Issue
6
Pages
2246-2265
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2787846545
Cited by
110
References
9
FWCI
3.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b01285
The paper
Boubia, B., Poupardin, O., Barth, M., Binet, J., Peralba, P., Mounier, L., Jacquier, E., Gauthier, E., Lepais, V., Chatar, M., Ferry, S., Thourigny, A., Guillier, F., Llacer, J., Amaudrut, J., Dodey, P., Lacombe, O., Masson, P., Montalbetti, C., . . . Broqua, P. (2018). Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b01285

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.